Mechanism review
Growth-hormone fragments vs secretagogues
Why two structurally different peptide families — lipolytic HGH fragments (AOD-9604, HGH 176-191) and GH secretagogues (CJC-1295, ipamorelin, tesamorelin) — co-exist in modern metabolic research.
Two different mechanistic strategies
The growth-hormone axis offers two distinct routes to influence adipose biology without supplying exogenous full-length GH. The first is fragment-based: truncated C-terminal sequences (HGH 176-191, AOD-9604) that retain the lipolytic pharmacophore but lack the IGF-1-mediated growth-promoting and insulin-antagonising effects of the parent hormone. The second is secretagogue-based: peptides that act on either the GHRH receptor (CJC-1295, tesamorelin) or the GHSR/ghrelin receptor (ipamorelin) to stimulate endogenous pulsatile GH release.
Why both families persist
Secretagogues recreate physiological GH kinetics — the pulsatile release pattern that drives downstream IGF-1 signalling, lean-mass support and adipose-tissue remodelling. Fragments isolate the lipolytic action while sidestepping the IGF-1 axis entirely, which is methodologically useful in studies designed to interrogate fat metabolism without GH's broader effects on insulin sensitivity or cell proliferation.
Evidence-base comparison
The secretagogue literature is substantially deeper. Tesamorelin completed Phase 3 trials (Falutz et al., NEJM 2007) in HIV-associated lipodystrophy and is MHRA-recognised in that narrow indication. CJC-1295 and ipamorelin have extensive Phase 1/2 pharmacokinetic and GH-response data. The fragment family is dominated by AOD-9604's Phase 2 obesity programme (which did not advance to Phase 3) and a smaller body of preclinical rodent literature.
Selecting between them for research
For experiments designed to interrogate adipose-tissue lipolysis with minimal off-target metabolic effects, the fragment family (especially AOD-9604) is the common reference. For experiments designed to study the GH axis or its downstream metabolic effects, the secretagogue family — usually CJC-1295 paired with ipamorelin — is standard. Tesamorelin is the GHRH-analogue reference in studies of visceral adiposity specifically.
See profiles: Tesamorelin · CJC-1295 / Ipamorelin · AOD-9604 · HGH Fragment 176-191.